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Abstract
The aim was to provide evidence on systemically treated patients with advanced
melanoma not represented in phase III trials to support clinical decision-making.
Analysis were performed on advanced melanoma patients diagnosed between
2014 and 2017 in the Netherlands, treated with immune- or targeted therapy, who
met ≥1 trial exclusion criteria. These criteria were derived from the KEYNOTE-006
and CHECKMATE-067/-066 phase III trials. Prognostic importance of factors asso-
ciated with overall survival (OS) was assessed with the Kaplan-Meier method, Cox
models, predicted OS probabilities of prognostic subgroups and a conditional infer-
ence survival tree (CIST). A nationwide population-based registry was used as data
source. Of 2536 systemically treated patients with advanced melanoma, 1004
(40%) patients were ineligible for phase IIII trials. Ineligible patients had a poorer
median OS (mOS) compared to eligible patients (8.8 vs 23 months). Eligibility
criteria strongly associated with OS in systemically treated ineligible patients
were Eastern Cooperative Oncology Group Performance Score (ECOG PS) ≥2,
brain metastases (BM) and lactate dehydrogenase (LDH) of >500 U/L. Patients
with ECOG PS of ≥2 with or without symptomatic BM had a predicted mOS of
6.5 and 11.3 months and a 3-year survival probability of 9.3% and 23.6%,
respectively. The CIST showed the strongest prognostic covariate for survival
was LDH, followed by ECOG PS. The prognosis of patients with LDH of
>500 U/L is poor, but long-term survival is possible. The prognosis of ineligible
patients with advanced melanoma in real-world was very heterogeneous and
highly dependent on LDH value, ECOG PS and symptomatic BM.
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1 | INTRODUCTION
In recent years, treatment options for advanced melanoma have
increased as immune- and targeted therapies became available. The
randomized controlled trials (RCTs) used for marketing approval for
these treatments showed major improvements in overall response
rate, progression-free survival and overall survival (OS) compared to
standard treatments.1
RCTs are considered the gold standard to determine efficacy of new
treatments. Strict inclusion and exclusion criteria are applied to create a
homogenous patient population. This improves the internal validity of
clinical trials which enables estimation of valid treatment effects of new
treatments. A large proportion of real-world patients with advanced mel-
anoma are not represented in clinical trials.2 Real-world patients not ful-
filling the RCT inclusion criteria (ineligible patients) are being treated
without evidence of the efficacy and safety in daily clinical practice.
Donia et al3 concluded that also ineligible patients might have benefited
from the introduction of new treatments.
However, the ineligible patient population is heterogeneous.
Additional information is needed to determine which subgroups of
ineligible patients do not benefit from these new treatments. More
efficient use of systemic treatment can spare patients severe
adverse events4,5 and perhaps reduce the financial burden for
society.6
What's new?
By necessity, randomized controlled trials (RCTs) exclude
many patients. However, these ineligible patients are often
still treated with new systemic therapies on an individual
basis. In this study, the authors examined how various sub-
groups of ineligible patients fared following treatment for
advanced melanoma. They found that several criteria were
strongly associated with prognosis in these patients, includ-
ing lactate dehydrogenase (LDH) levels. These results should
provide clinicians with a decision tree of prognostic factors
to help guide treatment decisions.
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In our study, the nationwide prospective population-based Dutch
Melanoma Treatment Registry (DMTR) was used to report clinical
outcomes of ineligible patients.7 Our study aimed to identify prognos-
tic factors for survival for systemically treated ineligible patients, to
predict survival for prognostic subgroups of ineligible patients and to
order the impact of prognostic factors with a decision tree to help
guide clinical decision-making.
2 | METHODS
2.1 | Study design and patients
Patients of 18 years and older, diagnosed with unresectable stage IIIC or
stage IV melanoma between January 1, 2014 and December 31, 2017,
were included. Criteria to distinguish ineligible from eligible patients were
derived from the KEYNOTE-006 and CHECKMATE-067/-066 phase III
trials.8-10 Patients were considered ineligible for potential trial participa-
tion if they met one or multiple of the following exclusion criteria:
• Brain metastasis or leptomeningeal metastasis
 In the DMTR data no distinction could be made between active
or not active brain metastasis
• Eastern Cooperative Oncology Group performance status (ECOG
PS) of ≥2
• Active autoimmune disease(s)
 Rheumatoid disease, systemic lupus erythematosus, vasculitis,
inflammable bowel disease (Crohn's or colitis ulcerosa)
• Immune-modulating medication
 Azathioprine or interferon
• Known history of Human Immunodeficiency Virus or AIDS
• Liver disease or failure or kidney failure
• Serious psychiatric disorder
 Schizophrenia, severe depression or psychosis
Dataset cutoff date was June 1, 2019. The medical ethics com-
mittee judged that informed consent was not necessary for the DMTR
and all patients were offered an opt-out possibility.
2.2 | Statistical analysis
Baseline patient and tumor characteristics of systemically treated
ineligible and eligible patients were analyzed with descriptive statis-
tics. OS estimates of these groups were estimated with the Kaplan-
Meier method. Survival times were calculated from the start of
systemic therapy until death or last follow-up. Median follow-up
time was estimated with the reverse Kaplan-Meier method.11 Within
the systemically treated ineligible patient population, univariable and
multivariable Cox proportional hazards regression models were used
to estimate the association of exclusion criteria and other clinically
relevant prognostic factors with OS.12 Variables assessed were lac-
tate dehydrogenase (LDH), Eastern Cooperative Oncology Group
Performance Score (ECOG PS), age, gender, metastases in ≥3 organ
sites, brain metastases, liver metastases, year of diagnosis, auto-
immune disease, psychiatric disorder and BRAF mutation. We pre-
sent the analyses of complete cases in Figure S1. The proportionality
assumption in the Cox models was investigated by means of scaled
Schoenfeld residuals.
For further analyses, we created prognostic subgroups of patients
based on the most important factors from the multivariable Cox model. We
used the full multivariable Cox model to predict the patient-specific proba-
bility of OS. For all subgroups the median OS (mOS) and 3-year OS proba-
bility were calculated based on these individual predicted probabilities.
To assess the potential benefit of systemic therapy in the absence of
a historical cohort, we created a control group by selecting systemically
treated and untreated ineligible patients diagnosed with advanced mela-
noma in 2013. We compared casemix-adjusted survival curves of this
2013 cohort with our study population. In the 2013 cohort of ineligible
patients, 29% received no systemic treatment, 14% received chemother-
apy, 37% ipilimumab or BRAF inhibitor monotherapy as first-line treat-
ment and 21% of the patients received another systemic therapy (patients
treated in named-patient or compassionate use programs or in trials).
We constructed a decision tree model using the recursive binary
partitioning approach. The method of Hothorn et al13 was used to create
a conditional interference survival tree (CIST). The variables used in the
model were gender, age, LDH, ECOG PS, number of organs with distant
metastases, brain and liver metastases, year of diagnosis and BRAF-
mutation. First, the model determines which variable is most strongly
associated with OS. Second, a cut-off value in this variable is calculated
that optimally splits the data creating two most prognostically different
subpopulations. The model then repeats these two steps taking the two
new nodes as the basis. The model stops if no variable significantly asso-
ciated with OS is left and no prognostic difference is seen when par-
titioning the subpopulation further.13
Data handling and statistical analyses were performed using the R
software system for statistical computing (version 3.6.1.; packages
tidyverse, lubridate, car, survival, survminer, partykit).
3 | RESULTS
From 2014 to 2017, 3460 patients were diagnosed with
unresectable stage IIIC and stage IV (advanced) melanoma prospec-
tively registered in the DMTR. Patients diagnosed with uveal mela-
noma, age of <18 years and patients with missing values to
determine eligibility or missing survival data were excluded from
further analyses. Of the remaining 3009 patients, 1004 (40%) sys-
temically treated patients with advanced melanoma were consid-
ered ineligible (Figure S2).
3.1 | Eligible vs ineligible patients
The main differences in characteristics between ineligible patients and
eligible patients were related to the exclusion criteria, such as the
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presence of brain metastases (n = 682, 67.9%), ECOG PS of ≥2
(n = 281, 28.0%) and the presence of active autoimmune diseases
(n = 141, 14.0%) in ineligible patients (Table 1). Besides these
differences in exclusion criteria, other baseline characteristics were
significantly more common in ineligible patients compared to eligible
patients, such as elevated LDH level of ≥250 U/L, stage IVM1c dis-
ease, liver metastasis, metastasis in ≥3 organ sites and the presence of
BRAF mutation (Table 1).
The mOS of systemically treated ineligible patients was
shorter compared to systemically treated eligible patients
(8.8 months (95%CI: 7.9-11.0) vs 23 months (95%CI: 21-27)). The
3-year OS probability was 22% (95%CI: 19-25) for ineligible
patients and 41% (95%CI: 38-43) for eligible patients (Figure 1).
The median follow-up of systemically treated ineligible patients
was 38 months.
3.2 | Treatment and clinical outcomes of ineligible
patients
The composition of the systemically treated ineligible patient group
and the exclusion criteria are shown in Table S3. A total of
862 (85.9% of the ineligible patients) patients would have been
excluded from trial participation, because of either brain metastases
or ECOG PS ≥2, or both. The first- and second-line treatments of inel-
igible patients are shown in Figure 2.
In the multivariable Cox model, ECOG PS ≥2, elevated LDH
≥500 U/L and the presence of symptomatic brain metastases and liver
metastases were negatively associated with OS. BRAF mutational sta-
tus was not associated with OS (Table 3).
Comparison of the casemix-adjusted survival curves of the
2013 cohort with our study cohort of 2014 to 2017 indicated that
OS for ineligible patients has increased when more systemic thera-
pies were available (mOS of 5.7 months vs 8.8 months, respec-
tively). The 3-year OS probability of the 2013 cohort was 7.5% vs
22% of our study cohort (Figure S4). The mOS of systemically
untreated ineligible patients diagnosed with advanced melanoma
from 2014 to 2017 (n = 327) was 2.4 (95% CI: 2.1-2.8) months
(Figure S5).
We created 18 subgroups of systemically treated ineligible
patients by combining the most important exclusion criteria from
the multivariable Cox model, ECOG PS, and brain metastases with
LDH level, as LDH level is an important prognostic factor for sur-
vival.12,14 Each subgroup was assessed for the predicted mOS and
3-year survival probability (Table 2). The predicted survival curves
of individual patients in the subgroups showed substantial prog-
nostic variation in survival between patients in a subgroup
(Figures S6 and S7). The covariates BRAF mutational status, LDH,
ECOG PS and brain metastases violated the proportionality
assumption. To keep interpretation easy and avoid overfitting,
time-dependent effects of these risk factors were not modeled
explicitly. The HRs have to be interpreted as averages over the
follow-up time. The predicted probability curves also represent
these averaged effects. The nonproportionality of BRAF mutation
was further investigated in a Cox model in which this variable was
entered as a stratification factor.
TABLE 1 Patient and tumor characteristics of systemically treated




(n = 1532) P value
Median age, year (range) 62 (19, 94) 64 (19, 94) .080
Age categories .035
<50 years 176 (17.5) 273 (17.8)
50-59 years 259 (25.8) 320 (20.9)
60-69 years 274 (27.3) 452 (29.5)
>70 years 295 (29.4) 487 (31.8)
Female 422 (42.0) 607 (39.6) .238
ECOG PS
0 357 (38.3) 1028 (67.1)
1 295 (31.6) 504 (32.9)
2 204 (21.9) —
≥3 77 (8.3) —
Unknown 71 —
LDH level <.001
Normal 528 (54.0) 1052 (69.8)
250-500 U/L 283 (28.9) 332 (22.0)
>500 U/L 167 (17.1) 124 (8.2)
Unknown 26 24
Stage <.001
IIIc 17 (1.7) 150 (9.8)
IV-M1a 22 (2.2) 172 (11.2)
IV-M1b 29 (2.9) 246 (16.1)
IV-M1c 934 (93.2) 962 (62.9)
Metastases in ≥3 organ sites 620 (61.9) 549 (35.8) <.001
Brain metastasis
No 308 (31.1) 1532 (100.0)
Yes, asymptomatic 237 (23.9) —
Yes, symptomatic 445 (44.9) —
Unknown 14 —
Liver metastasis 311 (31.7) 387 (25.4) .001
Auto-immune diseasea 141 (14.0) —
IM medicationb 4 (0.4) —
HIV or AIDS 1 (0.1) —
Psychiatric disorderc 51 (5.1) —
BRAF mutant 671 (66.8) 833 (54.3) <.001
Note: Values are n (%) unless otherwise indicated.
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group perfor-
mance status; IM, immune modulating; LDH, lactate dehydrogenase.
aRheumatoid disease, systemic lupus erythematosus, vasculitis, inflamma-
ble bowel disease (Crohn's or colitis ulcerosa).
bAzathioprine, interferon.
cSchizophrenia, major depression, psychosis and other psychiatric
disorders.
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The conditional inference survival tree resulted in six subgroups
(Figure 3). The covariate with the strongest association with survival
was LDH. For patients with an LDH level of >500 U/L, other
covariates did not significantly influence the OS. The most prognostic
covariate in the subgroup of patients with a normal or LDH level of
250 to 500 U/L was ECOG PS followed by symptomatic brain
metastases.
3.3 | BRAF mutational status
We performed an additional analysis of BRAF-mutant vs BRAF wild-
type melanoma because BRAF mutational status was not associated
with OS in the multivariable Cox model (Table 3). Baseline character-
istics and the first-line systemic therapies of BRAF wild-type and
BRAF-mutated melanoma patients are shown in Table S8 and
Figure S9, respectively . The casemix-adjusted OS curves showed
that the small survival benefit in favor of the BRAF mutated mela-
noma established in the first 6 months, disappeared after 10 months
(Figure S10).
4 | DISCUSSION
Our study focused on clinical outcomes of ineligible advanced
melanoma patients treated with systemic therapy in real-world.
There is no RCT evidence to justify treatment in these patients,
but our study fills this knowledge gap and provides guidance in
shared decision-making. Forty percent of the systemically treated
patients were considered ineligible following the exclusion criteria
of phase III trials.8-10 Although OS of systemically treated ineligi-
ble patients was significantly lower than the OS of systemically
treated eligible patients, the 3-year OS probability of ineligible
patients was still 22%. There was a high variation in (predicted)
OS within the ineligible patient population, except for most sub-
groups with an LDH level of >500 U/L. The decision tree (CIST)13
technique identified clinically interesting prognostic subgroups
that can be used to prognostically stratify and inform ineligible
patients in daily practice.
F IGURE 1 Overall survival of
systemically treated ineligible and
eligible patients estimated with the
Kaplan-Meier method [Color figure
can be viewed at
wileyonlinelibrary.com]
F IGURE 2 First- and second-line systemic treatment of ineligible
patients [Color figure can be viewed at wileyonlinelibrary.com]
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TABLE 2 Subgroups of ineligible patients with predicted median overall survival and median of predicted 3-year survival probability based on
the multivariable Cox model
ECOG PS Brain metastasis LDH level n Predicted mOS (months) 3-year survival (%)
0-1 Absent normal 82 22.7 44.5
0-1 Absent 250-500 U/L 32 15.4 33.1
0-1 Absent >500 U/L 14 7.9 15.3
0-1 Asymptomatic normal 119 16.4 35.1
0-1 Asymptomatic 250-500 U/L 63 9.9 21.0
0-1 Asymptomatic >500 U/L 16 6.0 7.2
0-1 Symptomatic normal 191 11.9 25.0
0-1 Symptomatic 250-500 U/L 94 7.2 12.4
0-1 Symptomatic >500 U/L 21 5.0 3.7
≥2 Absent normal 53 11.3 23.6
≥2 Absent 250-500 U/L 50 7.6 14.1
≥2 Absent >500 U/L 65 4.8 3.2
≥2 Asymptomatic normal 3 11.0 22.7
≥2 Asymptomatic 250-500 U/L 6 6.2 8.1
≥2 Asymptomatic >500 U/L 10 4.8 3.1
≥2 Symptomatic normal 37 6.5 9.3
≥2 Symptomatic 250-500 U/L 18 4.7 3.1
≥2 Symptomatic >500 U/L 24 3.4 0.3
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; mOS, median overall survival.
F IGURE 3 Conditional inference survival tree incorporating disease and patient variables into prognostic models for survival, based on year
of diagnosis, age, gender, ECOG PS, LDH level, distant metastases, brain- and liver metastases and BRAF mutational status. P-values are from log-
rank statistics
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In-depth postapproval research cannot replace RCTs, but it is
necessary to try to substantiate the effectiveness of using new sys-
temic treatments in real-world patients. The distinction in eligibility
for trial participation is factitious. Eligibility depends on having one
or multiple exclusion criteria that were once defined for phase III tri-
als, but not all exclusion criteria are equally important with regard to
TABLE 3 Cox model of systemically treated ineligible patients for the association of prognostic factors with overall survival
Univariable Multivariable
n HR (95% CI) P value n HR (95% CI) P value
Year of diagnosis
2014 203 1 173 1
2015 262 0.91 (0.75-1.12) .383 226 0.84 (0.67-1.05) .129
2016 244 0.76 (0.61-0.93) .009 219 0.70 (0.56-0.87) .002
2017 295 0.73 (0.59-0.91) .004 264 0.61 (0.48-0.77) <.001
Age
≤50 176 0.70 (0.56-0.87) .002 148 0.65 (0.51-0.84) .001
50-59 259 0.84 (0.69-1.02) .08 228 0.79 (0.64-0.98) .032
60-69 274 1 245 1
≥70 295 0.98 (0.81-1.18) .792 261 1.02 (0.83-1.24) .885
Gender
Male 582 1 511 1
Female 422 0.90 (0.78-1.04) .149 371 0.91 (0.78-1.07) .245
ECOG PS
0 357 1 342 1
1 295 1.46 (1.21-1.75) <.001 278 1.35 (1.11-1.65) .003
≥2 281 2.09 (1.75-2.51) <.001 262 1.95 (1.52-2.5) <.001
LDH
Normal 528 1 475 1
250-500 U/L 283 1.44 (1.21-1.7) <.001 259 1.23 (1.02-1.49) .03
>500 U/L 167 2.64 (2.17-3.2) <.001 148 1.89 (1.49-2.41) <.001
Metastases in ≥3 organ sites
No 382 1 339 1
Yes 620 1.57 (1.35-1.83) <.001 543 1.25 (1.03-1.51) .021
Brain metastasis
Absent 308 1 295 1
Asymptomatic 237 0.95 (0.78-1.16) .614 208 1.31 (0.98-1.75) .069
Symptomatic 445 1.25 (1.06-1.48) .01 379 1.71 (1.34-2.18) <.001
Liver metastasis
No 671 1 602 1
Yes 311 1.64 (1.4-1.9) <.001 280 1.22 (1-1.48) .049
Auto-immune disease
No 863 1 754 1
Yes 141 0.71 (0.57-0.89) .003 128 1.02 (0.77-1.35) .892
Psychiatric disorder
No 953 1 835 1
Yes 51 0.69 (0.49-0.99) .044 47 0.93 (0.62-1.4) .721
BRAF-mutant
No 333 1 302 1
Yes 671 1.06 (0.91-1.24) .47 580 0.94 (0.79-1.12) .474
Abbreviations: CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; LDH, lactate dehydrogenase.
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the prognosis and/or effect of treatment (ie, psychiatric disorder and
immune-modulating medication). The ineligible patient population is
heterogeneous in itself and with different statistical approaches, we
attempted to provide in-depth evidence on what effect exclusion
criteria have on survival in the real-world.
In our study, 86% of systemically treated ineligible patients had
brain metastasis, ECOG PS of ≥2 or both. Brain metastases and ECOG
PS were combined with LDH level, a nonexclusion criterion that is
generally known for its prognostic and predictive importance, to cre-
ate subgroups.12,14 For subgroups of patients with (a)symptomatic
brain metastases, the prognosis was relatively good, provided that
ECOG PS was ≤1 and LDH level was normal. The decision tree (CIST)
model also showed that ineligible patients with an LDH level of
>500 U/L were a prognostic subgroup with poor survival. We previ-
ously showed the dismal prognosis in this group of patients and pro-
posed switching to ICI upon response to BRAF(/MEK-)-inhibition with
LDH normalization as a potential strategy to obtain long-term survival
in these patients.15 This information supports well-informed use of
systemic therapy in this patient group.
4.1 | Clinical benefit
It is important to estimate the clinical benefit of systemic treat-
ment in ineligible patients to decide whether possible treatment
benefit is worth the risk of side-effects for individual patients and
the financial burden for society. Donia et al2,3 found that the
(unadjusted) survival of ineligible patients improved over time and
suggested that these patients might have benefited from systemic
treatment. In the Netherlands, there are no guidelines for patients
with advanced melanoma recommending systemic treatment for
specific subgroups. Results from RCTs have to be extrapolated to
the real-world population. For specific subgroups of patients, the
choice to offer systemic therapy is, in most cases, based on the
expertise of the medical team. In general, the interpretation of
observational data for the effectiveness of treatment is compli-
cated by the lack of a comparator. Moreover, a clear definition
of significant clinical benefit is lacking. The American Society of
Clinical Oncology (ASCO) Value Framework16 and the European
Society of Medical Oncology (ESMO) Magnitude of Clinical Bene-
fit Scale (MCBS)17,18 were developed to assess the clinical benefit
of new cancer therapies in clinical trials. However, lack of real-
world comparison prohibits translation of these scales into daily
practice.
We attempted to estimate the magnitude of the benefit from sys-
temic treatment by comparing our study cohort to a surrogate control
group from the DMTR. This surrogate control group was comprised of
patients comprised of both systemically treated and untreated ineligi-
ble patients diagnosed in 2013 when only chemotherapy, ipilimumab
and BRAF-inhibitors (dabrafenib and vemurafenib) monotherapy were
available as standard treatments outside a trial setting. We observed a
mOS benefit of 3.1 months and a 3-year survival probability increase
of 14% to 22% of our study cohort (Figure 3). This suggests that
ineligible patients have benefitted from systemic treatments. We are
aware of the statistical limitations of the comparison with the artifi-
cially created “control group”. However, HRs of year of diagnosis
2016 and 2017 from the Cox also indicate that with the availability of
more effective immune and targeted therapies, OS has improved for
systemically treated trial-ineligible patients with advanced melanoma
in the Netherlands. Importantly, the full potential of ipilimumab plus
nivolumab combination therapy may not have been achieved yet,
because it only became available in the Netherlands in November
2016.
4.2 | BRAF mutational status
A high proportion of systemically treated ineligible patients had a
BRAF-mutated melanoma. For patients who are in poor condition,
which can be partly due to advanced melanoma, or patients with brain
metastases (or both), the threshold to start with targeted therapy may
be low. Targeted therapy for advanced melanoma is known for its
potential dramatic antitumor activity and short time to first
response.19 A notable finding in our Cox model was that BRAF-
mutational status was not associated with OS. The initial survival
advantage of patients with BRAF-mutated melanoma did not persist.
Our results do not appear to support an alleged synergy of (sequen-
tial) treatment with targeted- and immunotherapy in the ineligible
patient population.20
4.3 | RCT recommendations
Currently, evidence on the effectiveness of systemic treatment in
patients with melanoma brain metastases is being generated in phase
II clinical trials.21,22 In our study, 27% of all patients with advanced
melanoma had (a)symptomatic brain metastases. We found that of the
trial exclusion criteria, that having brain metastasis was one of
the most important prognostic factors for survival. We observed,
on the other hand, that some of these patients with brain metastasis
could still reach long-term survival. Therefore, we advocate that
patients with brain metastases should be included in RCTs. This will
lead to a more representative casemix and an increase in evidence for
effective systemic treatment of patients.23
4.4 | Limitations
There are limitations to our study. We used observational data of a
nationwide population-based registry to analyze daily practice.
Systemic treatment of ineligible patients was dependent on consid-
erations of the medical team and patient. The mOS of untreated
ineligible patients in the same period was less than 3 months
(Figure S6). This indicates that the selection of ineligible patients
suitable for treatment was justified. However, we were not able to
estimate the influence of systemic treatment, because we do not
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know what the outcomes would have been if untreated patients
would have been treated and vice versa. The effectiveness of indi-
vidual targeted or immunotherapies could not be investigated due
to confounding by indication. We did not analyze safety of sys-
temic treatment, and data on quality of life and exact treatment
costs were not available, but these topics are important to further
improve clinical decisions for starting systemic therapy in ineligible
patients.
4.5 | Strengths
Although we used registry data, we argue the data are of high quality
since trained data managers check electronic patient records every
3 months with quality control of data by medical oncologists. The
DMTR has nationwide coverage and includes patients without treat-
ment as well.7
Results from our study can be used to inform patients on proba-
ble prognosis to make well-informed shared-decision and set realistic
treatment goals. In patients with (multiple) unfavorable prognostic
factors refraining from systemic treatment should be seriously consid-
ered. Our real-world clinical results can be used in the treatment of
future ineligible patients. The CIST method could also be used in
future research for the entire patient population of advanced mela-
noma patients to further improve shared-decision making. Further-
more, if individual trial data would be publicly available, comparison of
RCT data with real-world data could lead to a better understanding of
clinical outcomes.
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